NEW YORK, NY / ACCESS Newswire / September 10, 2025 / Big Interview, the leader in AI-powered job training and interview ...
Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) The systematic review included 35 publications on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback